SUMMARY: A new report from the Centers for Disease Control and Prevention indicates that we are losing ground in the battle against so-called superbugs -- the harmful or deadly bacteria resistant to nearly all our antibiotic defenses. William Brangham talks to Dr. Arjun Srinivasan, who works on infection control at the CDC and helped compile the report, about how we can prevent these dangerous infections.
SUMMARY: Deadly antibiotic resistance is predicted to eclipse the number of people affected by cancer by 2050, and one of the biggest causes is overuse. A new study out Monday found the use of antibiotics worldwide has increased 65 percent in 15 years. Science correspondent Miles O'Brien joins Lisa Desjardins to discuss the latest research into the growing crisis.
SUMMARY: As high-density, industrial-scale livestock farms have become fertile breeding grounds for disease, they've also become a major source of drug-resistant superbugs. Science correspondent Miles O'Brien and economics correspondent Paul Solman team up to report on how scientists are studying how superbugs can get into the food supply.
SUMMARY: For decades, almost all factory-farmed chickens were raised on antibiotics. But low doses of “maintenance” antibiotics can spur bacteria to build resistance, creating superbugs. Economics correspondent Paul Solman and science correspondent Miles O'Brien report team up to examine why one major chicken producer went antibiotic-free while most still continue the practice.
SUMMARY: Each year, superbugs -- viral bacterial infections resistant to common antibiotics -- infect more than two million Americans, killing at least 38,000. As the list of antibiotic-resistant bacteria grows, so have the extraordinary efforts to prevent the spread of infection from patient to patient. Science correspondent Miles O'Brien and economics correspondent Paul Solman team up for a report.
SUMMARY: As current antibiotics begin to lose their punch, there's an economic reality putting a damper on development. Since every use of an antibiotic drives resistance, and doctors are reluctant to use a drug until there's no alternative, why would a drug company spend a fortune? Economics correspondent Paul Solman and science correspondent Miles O'Brien continue their look at the hunt for new drugs.
SUMMARY: As drug-resistant infections proliferate, financial barriers are preventing the pharmaceutical industry from investing in new drugs to fight off superbugs. Economics correspondent Paul Solman, in a series of reports with science correspondent Miles O'Brien, explores how researchers could be incentivized to develop new antibiotics.
SUMMARY: For the first time in the U.S., a human embryo has been successfully edited to correct an inherited condition. By snipping out the gene that causes a specific heart disease, scientists also ensured the disease could not be passed down. But the milestone raises significant scientific and ethical questions. Hari Sreenivasan speaks with Jessica Berg of Case Western Reserve University Law School.
SUMMARY: A 49-year-old Pennsylvania woman has been found carrying a strain of E-coli that is resistant to last-resort antibiotics, which researchers say marks the first appearance of a drug-proof bacteria on U.S. soil. Scientists in Pennsylvania are working with the Centers for Disease Control to find a way to fight the superbug. Hari Sreenivasan talks to Dr. Beth Bell of the CDC for more.
HARI SREENIVASAN (NewsHour): A sobering new development with superbugs and public health concerns about the limited effect of antibiotics.
For the first time in the U.S., a person has been found to be carrying a strain of E-coli (Escherichia coli) that's resistant to antibiotics of last resort. The Washington Post reported the strain was discovered last month in a 49-year-old Pennsylvania woman. She was resistant to Colistin. And researchers said it — quote — “heralds the emergence of a truly pan-drug-resistant bacteria.”
Dr. Beth Bell is with the Centers for Disease Control and Prevention. And she is now working with Pennsylvania officials. She's the director of the National Center for Emerging and Zoonotic Infectious Diseases.
Thanks for joining us.
First, how — what is so distinct about these findings?
DR. BETH BELL, Centers for Disease Control and Prevention: Colistin is an antibiotic that we have already had for quite a long time, but we use it as a last line.
So, it's our drug of last resort. And so when patients are infected with some of these superbugs that we have talked about before, where the strain is resistant to pretty much every antibiotic, we rely on Colistin as the last resort.
And what we find here in this patient, the bacteria that infected this patient, is that her strain contains one of these mobile genes that confers resistance to Colistin. So, because bacteria can spread these mobile genes among themselves, it sets off a situation where we can see a bacteria that's resistant to every known antibiotic. And, of course, that is a very frightening prospect for all of us.
HARI SREENIVASAN: Right.
So, when I am go to the pharmacy, and I'm prescribed something like azithromycin or something, it's pretty low on the scale of the arsenal that doctors have. So, this is the top end. There is nothing after this. That means that the patient is untreatable, and that means there is a, what, greater chance that they might die because of this?
DR. BETH BELL: Sure.
There’s — we luckily haven’t seen actual bacteria that are resistant to every single antibiotic here in the United States. But there are reports of this in other parts of the world, and these patients have a very high mortality rate. It’s extremely difficult to treat them. And, again, this raises the specter of a post-antibiotic era.
